Next‐generation inhibitors, such as quizartinib or gilteritinib, are more specific and potent FLT3 inhibitors with more favourable toxicity profiles; however, to date, these drugs are approved only for acute myeloid leukaemia, and thus no data on their activity in solid tumours are available.41 The gene discussed is FLT3; the disease is acute myeloid leukemia.